Clinical Trials Directory

Trials / Completed

CompletedNCT01430611

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
666 (actual)
Sponsor
Sanofi Pasteur, a Sanofi Company · Industry
Sex
All
Age
2 Years – 6 Years
Healthy volunteers
Accepted

Summary

This study is part of the post-licensure commitment to evaluate the safety and immunogenicity of Meningo A+C vaccine in healthy Chinese children 2 to 6 years of age. Primary Objective: To demonstrate the non-inferiority in terms of seroconversion rate for serogroups A and C, 30 days after a single dose of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine. Secondary Objective: * To describe the immunogenicity for serogroups A and C, 30 days after administration of the study vaccines given as a single dose. * To describe the full reactogenicity profile after administration of the study vaccines given as a single dose.

Detailed description

Eligible participants will receive one injection of either Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine or Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine and will be monitored for safety and immunogenicity for up to 30 days post-vaccination.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMeningococcal (Groups A and C) Polysaccharide Vaccine0.5 mL, Subcutaneous
BIOLOGICALMeningococcal (Groups A and C) Polysaccharide Vaccine0.5 mL, Subcutaneous

Timeline

Start date
2011-08-01
Primary completion
2012-08-01
Completion
2012-11-01
First posted
2011-09-08
Last updated
2014-05-08
Results posted
2014-05-08

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT01430611. Inclusion in this directory is not an endorsement.